The mid-1990s saw the emergence of the first disease-modifying therapies (DMTs) for multiple sclerosis (MS), all of which were injectables with largely similar efficacy. 1 In the last few years, the treatment landscape has shifted considerably, encompassing therapies with a range additional routes of administration (oral, intravenous), higher efficacies than the initial therapies, and with considerably more serious adverse effects, including progressive multifocal leukoencephalopathy. 1 While the expansion of treatment options offers the opportunity to personalize therapy for the individuals with MS, the complexity of the treatment landscape and volume of evidence related to those treatments pose challenges for clinicians and patients. In this context, two groups, the European Committee of Treatment and Research in Multiple Sclerosis (ECTRIMS) in cooperation with the European Academy of Neurology (EAN) and the American Academy of Neurology (AAN), have recently released guidelines regarding the use of DMTs in MS. 2, 3 Despite the regional designations in the names of these guidelines, both will gain the attention of clinicians worldwide who will need to decide whether to adopt them and how to address local resource or regulatory constraints which may impede their implementation.
According to the Institute of Medicine, "Clinical Practice Guidelines are statements that include recommendations intended to optimize patient care that are informed by a systematic review of evidence and an assessment of the benefits and harms of alternative care options." 4 Interested readers are referred elsewhere for a discussion of the science of guideline development, quality assessment, and implementation. [4] [5] [6] Ideally, such guidelines inform decision-making by clinicians and patients, 4 promote consistency of care and use of interventions with demonstrated benefit, discourage the use of ineffective interventions, and support quality improvement activities and policy decisions. 7 However, MS clinicians face a conundrum; although the ECTRIMS/EAN and AAN guidelines make similar recommendations for some clinical scenarios, they make somewhat different recommendations for others.
Let us begin by reviewing the broad similarities. First, both guidelines recommend discussing the use of DMT for individuals who present with a clinically isolated syndrome (CIS) and have brain lesions suggesting MS but who do not fulfill diagnostic criteria for MS, and indicate that the highest quality data exist for the use of glatiramer acetate and interferon-beta. Second, both recommend (early) initiation of DMT in patients with active relapsing-remitting multiple sclerosis (RRMS), as defined by relapses or magnetic resonance imaging (MRI) activity or both. Guidance as to the choice of therapy is relatively limited however, leaving each clinician-patient dyad to independently consider factors such as patient characteristics, comorbidities, disease severity, and adherence, as well as mechanism of action, efficacy, availability, and safety of available therapies. The AAN guideline recommends alemtuzumab, fingolimod, or natalizumab for "very active MS" but does not explicitly define "very active MS." Third, the guidelines advocate for continuing DMT in persons with MS who are stable as assessed clinically and by MRI. Fourth, both guidelines noted that clinical trials of interferon-beta, glatiramer acetate, and fingolimod did not show benefit in primary progressive multiple sclerosis (PPMS) and recommended offering ocrelizumab to persons with PPMS who may benefit. While neither guideline specifies which individuals are likely to benefit, the ORATORIO trial enrolled persons aged 18-55 years, with an Expanded Disability Status Scale (EDSS) score of 3.0-6.5 (i.e. ambulatory) and cerebrospinal fluid with an elevated IgG index or at least one oligoclonal band. 8 It is unknown whether persons with PPMS with differing characteristics would experience Disease-modifying therapy in multiple sclerosis: Two guidelines (almost) passing in the night the benefits observed in the ORATORIO trial. Finally, the guidelines are also consistent in emphasizing the importance of MRI in monitoring the disease and treatment effectiveness in conjunction with clinical assessments. However, only the AAN guideline explicitly addresses the need to monitor individuals with RRMS who did not start DMT.
With respect to switching therapy, the EAN/ ECTRIMS guideline addressed the narrow question of the choice of therapy in individuals treated with interferon-beta or glatiramer acetate who experience early disease activity, defined as relapses, disability progression, or MRI activity. The recommendation was to offer a more efficacious therapy (fingolimod, cladribine, alemtuzumab, natalizumab, and ocrelizumab) rather than switching between interferon-beta and glatiramer acetate. The AAN guideline also recommends switching DMT in the presence of disease activity on any DMT but as noted earlier makes specific recommendations for more efficacious therapy only in the setting of "very active MS." Furthermore, the AAN guideline suggests considering a DMT switch in the setting of injection fatigue and among individuals taking natalizumab if they are or become JC virus antibody positive (index ≥ 0.9), both situations that the EECTRIMS/EAN guideline does not explicitly address. Recommendations regarding changes in therapy were hampered by the lack of head-to-head comparisons between the more effective therapies and lack of guidance around sequencing therapies which may have prolonged immunologic effects after cessation.
The guidelines also differed in several areas. The most marked divergence in the guidelines arose in the setting of pregnancy. Given that MS typically presents during childbearing years, management of MS before, during, and after pregnancy is a salient issue. In untreated women with MS, annualized relapse rates decrease during the third trimester and increase post-partum. 9 This pattern is maintained in women treated with interferon-beta or glatiramer acetate who stop these therapies before conception. [10] [11] [12] However, in women who stop more effective therapies such as fingolimod or natalizumab before conception, the annualized relapse rate increases during pregnancy and post-partum. [12] [13] [14] While it is uncertain whether these differences in relapse rate reflect inherent differences in the disease activity of women using different DMT, or rebound effects of stopping highly effective agents in the specific setting of pregnancy, these differences in outcomes are clinically relevant. The AAN guideline cautiously suggests that women be counseled to stop their DMT pre-conception, that DMTs be discontinued if accidental exposure occurs during pregnancy, and that DMTs not be started during pregnancy-unless the risk of disease activity outweighs the benefits. The ECTRIMS/EAN guideline cautiously suggests a more active approach with explicit recommendations in the setting of disease activity. Specifically, if there is a high risk of disease activity on stopping therapy, glatiramer acetate and interferon-beta could be continued until conception or possibly throughout pregnancy. In women with highly active disease, natalizumab could be used during pregnancy after counseling regarding the risks, 14, 15 or alemtuzumab could be used with pregnancy planned to occur at least 4 months later (weak recommendation). The exclusion of pregnant women from clinical trials of DMT on the basis of concerns about fetal risks leads to the lack of rigorously collected data in controlled settings 16 and contributes to the challenges of developing evidence-informed guidelines.
The approach to secondary progressive multiple sclerosis (SPMS) also differs. Although the AAN guideline recommends against the use of mitoxantrone unless anticipated benefits greatly outweigh the risks, the ECTRIMS/EAN guideline (weakly) recommends considering mitoxantrone for active SPMS with discussion of risks and benefits. The discrepancy likely reflects differences in balancing the risks and benefits of this therapy in the context of limited alternatives for active SPMS. Notably, the ECTRIMS/EAN guideline also suggested ocrelizumab, cladribine, and interferon-beta as possible therapies for active SPMS, since they are licensed for active relapsing forms of MS. In contrast, the AAN guideline proposes potential guidelines for stopping DMT in SPMS. This latter issue is not addressed by the ECTRIMS/EAN guideline but remains an important point of clinical controversy. In ambulatory persons with SPMS without relapses or MRI evidence of disease activity, injectable and oral-approved DMTs do not delay disability progression 17 as measured by a measure dominated by ambulation, the EDSS. 18 The efficacy of DMTs in non-ambulatory persons with SPMS has not been evaluated, making it uncertain whether there are benefits with respect to preserving vision, cognition, and upper limb function which outweigh the risks and costs of therapy. The ECTRIMS/EAN and AAN guidelines both recognized the importance of MRI for monitoring individuals being treated with DMT. However, they differed with respect to the specificity of their recommendations. The ECTRIMS/EAN guideline recommended standardization of MRIs and scanning at specific intervals, whereas the AAN did not provide explicit guidance as to the intervals when MRIs should be obtained.
What drove the differences in these recommendations? First, the research questions were slightly different (Table 1 ). In the ECTRIMS/EAN guideline, the research questions were developed by representatives of advocacy groups, MS clinical experts, and methodologists with expertise in systematic reviews and guideline development. The questions in the AAN guideline were developed by a broader group of clinical experts, AAN methodologists, stakeholders such as people with MS and representatives of advocacy In people with RRMS who experience disease activity while on a DMT, is changing to a different DMT superior to continuing present DMT in terms of relapse rate and MRI T2 or gadolinium lesion activity?
In patients with relapsing MS treated with interferon or glatiramer acetate and evidence of early disease activity (relapses and/or disability progression and/or MRI activity at 6/12 months), what is the benefit of switching between interferon and glatiramer acetate versus moving to more efficacious drugs? In people with progressive MS, are DMTs superior to placebo or other DMTs as measured by relapse rate or in-study disease progression?
In patients with primary progressive MS, what is the benefit of treating with a DMD compared to no treatment? What are the adverse effects of DMTs in patients with MS compared with placebo (adverse effect-related discontinuation and serious or lifethreatening adverse effects)? In people with clinically isolated syndromes, are DMTs superior to placebo in decreasing the risk of conversion to clinically definite MS?
In patients with CIS (regardless of whether they fulfill the criteria of definite MS) what is the benefit of starting treatment with a DMD compared to no treatment? In patients with relapsing MS treated with DMDs, does the presence of early disease activity (relapses and/or disability progression and/or MRI activity at 6/12 months) predict an increased risk of future disability? In patients with relapsing MS who stop taking a highly efficacious drug, is there a risk of return and/or rebound of their disease activity (increased risk of relapses, disability progression, and/or MRI activity)? groups, as well as methodologists and members with expertise in systematic reviews and guideline development. Second, the approach to identifying the evidence was slightly different; unlike the AAN guideline, the ECTRIMS/EAN guideline incorporated observational studies as well as randomized controlled trials (RCTs) and systematic reviews for the clinical management questions. Third, the quality appraisal processes demonstrated slight differences. Uniquely, recommendations made in the AAN guideline were revised and re-voted upon following a public comment period. Finally, variation in practice tends to arise when highquality evidence to inform decision-making is lacking. Of these, the most influential factor is likely the last one. Thus, the differences in the recommendations of the two guidelines as well as areas where recommendations were not made highlight the areas where more, or higher quality evidence, or both is urgently needed to inform clinical decision-making.
Most of the studies reviewed for these guidelines were typical explanatory clinical trials which focused on relatively simple assessments of DMT efficacy, that is, is drug A better on average than placebo, or is drug A better than drug B among ideal conditions? In clinical practice, the questions and people of interest are different. What is the best drug for this person, who might not have met the eligibility for any clinical trial due to age, comorbidities, or other factors? These and other practical clinical questions such as whether early aggressive therapy versus escalation approaches provide superior longterm outcomes must be addressed using comparative effectiveness studies and pragmatic RCTs. The lack of standard definitions for disease activity in MS, including very active MS, and uncertainty regarding the optimal treatment target in MS, as well as the optimal interval for MRI monitoring are limitations that inhibit the design and applicability of such studies. International consensus about these definitions and harmonization of data collection and quality across registries will be important to enhance comparability of future studies and ease translation of study findings into clinical practice. Finally, clinical trials of DMT in populations with special considerations such as youth with MS, 19 pregnant women, 16 older individuals, those with comorbidities, 20 and persons with progressive MS who are non-ambulatory are also needed urgently.
We must thoughtfully and deliberately design studies to address these clinical management questions as a community, so that future guidelines will not suffer from the vagaries of insufficient evidence.
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